PRELUDE THERAPEUTICS INC

PRLDNASDAQ

🏆 #3636 by market capEarnings Nov 11US Equity

$3.96▲ $0.07 (+1.80%)

After hours · at close

🔔

Track PRLD

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 1.8%

7d▼ 18.4%

14d▼ 12.4%

30d▼ 27.5%

ytd▲ 37.0%

1y▲ 187.0%

🏦Market Cap

$225M

Small Cap

📈Revenue Growth (YoY)

+73.4%

High Growth

📊Gross Margin

98.3%

High

💵FCF Margin

-148.3%

Thin

⚖️P/S Ratio

10.1x

Elevated

Otter Score

Fair

Trading Snapshot

Day Range: $3.93 – $4.03
52-Week Range: $1.15 – $6.83
Volume: $3.42B
Avg Volume: $3.77B
Shares Outstanding: 56.9M
Next Earnings: Nov 25, 2026

Fundamentals Snapshot

Annual Revenue: $12M
Last Q Revenue: $6M
P/E Ratio: -5.0
P/S Ratio: 10.1x
EPS (TTM): $-0.61
Dividend Yield: 0.00%
Dilution (1yr): −17.1%

Why Investors Own PRLD

✓High-growth profile — revenue up +3.5% YoY with expanding US Equity exposure.
✓Healthy economics — 34% gross margin and 26% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PRELUDE THERAPEUTICS INC

PRLD

Financial Trends

Revenue

$12M▲ +73.4% YoY

Gross Margin

85.9%▼ −14.1% YoY

Operating Income

−$105M▼ −25.2% YoY

Free Cash Flow

−$56M▼ −45.6% YoY

Shares Outstanding

63.0M▼ −17.1% YoY

Net Cash

$17M▲ +$23M YoY

StockOtter · stockotter.space

About PRELUDE THERAPEUTICS INC

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.

🦦